SCHEMBL1928147

SCHEMBL1928147

COc1ccc2ncc(N)cc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.58
PDGFRA P16234 4/20 0.58
ALDH1A1 P00352 4/20 0.58
HPGD P15428 2/20 0.58
F2 P00734 1/20 0.58
GLA P06280 1/20 0.58
EGFR P00533 3/20 0.57
NCF1 P14598 1/20 0.54
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
BACE1 P56817 1/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
NPC1 O15118 3/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
RAB9A P51151 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2811188 0.86 HPGDS (0.60) PDGFRBPDGFRAALDH1A1EGFRNCF1
SCHEMBL620427 0.86 ALDH1A1 (0.54) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL7028923 0.85 ALDH1A1 (0.70) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL434861 0.80 PDGFRB (0.59) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL10556996 0.79 PDGFRB (0.62) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL9156972 0.79 ALDH1A1 (0.62) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL621672 0.79 PDGFRB (0.58) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL27930034 0.79 PDGFRB (0.58) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL444746 0.79 PDGFRB (0.58) PDGFRBPDGFRAALDH1A1HPGDF2
SCHEMBL27918947 0.79 PDGFRB (0.58) PDGFRBPDGFRAALDH1A1HPGDF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119639239-A Environment-friendly flame-retardant new energy charging pile cable 瑞安达电缆有限公司 2025-03-18 CN claimed
CN-1930105-B Process for preparing fluoroaromatic compounds from aminoaromatic amine compounds RHONE POULENC CHIMIE 2010-12-08 CN claimed
US-20070276168-A1 Method For Preparation Of A Fluoroaromatic Compound From An Aminoaromatic Compound RHODIA CHIMIE (FR) 2007-11-29 US claimed
CN-1930105-A Process for preparing fluoroaromatic compounds from aminoaromatic amine compounds RHONE POULENC CHIMIE (FR) 2007-03-14 CN claimed
EP-1713750-A1 METHOD FOR PREPARATION OF A FLUOROARMATIC COMPOUND FROM AN AMINOAROMATIC AMINE COMPOUND RHODIA CHIMIE (FR) 2006-10-25 EP claimed
WO-2005082820-A1 METHOD FOR PREPARATION OF A FLUOROAROMATIC COMPOUND FROM AN AMINOAROMATIC AMINE COMPOUND. RHODIA CHIMIE (FR) 2005-09-09 WO claimed
WO-2025076284-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME DELPHIA THERAPEUTICS, INC. (US) 2025-04-10 WO disclosed
CN-119639239-A Environment-friendly flame-retardant new energy charging pile cable 瑞安达电缆有限公司 2025-03-18 CN disclosed
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) 2019-08-06 US disclosed
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (US) 2019-08-06 US disclosed
US-20190010126-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS Sanford Burnham Prebys Medical Discovery Institute 2019-01-10 US disclosed
US-9884826-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-02-06 US disclosed
US-9884826-B2 Sulfonamide compounds and uses as TNAP inhibitors SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2018-02-06 US disclosed
US-6603005-B2 Bactericides AVENTIS PHARMA S.A. (FR) 2003-08-05 US disclosed
WO-2003018021-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS AMGEN INC. (US) 2003-03-06 WO disclosed
US-20020177606-A1 Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them NOVEXEL (FR) 2002-11-28 US disclosed
WO-2002072572-A1 QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 2002-09-19 WO disclosed
US-20020111492-A1 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them NOVEXEL (FR) 2002-08-15 US disclosed
WO-2002040474-A2 HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIMICROBIAL AGENTS AVENTIS PHARMA S.A. (FR) 2002-05-23 WO disclosed
US-5442065-A Antitumor agents BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1995-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10370333-B2 Sulfonamide compounds and uses as TNAP inhibitors TNNI3, TNKS1BP1, TNNT2 PDGFRB 3815/4885PDGFRA 2401/4885ALDH1A1 3674/4885
US-20020111492-A1 Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them SYNJ1, NCAPD2, SYNJ2 PDGFRB 3444/4885PDGFRA 2639/4885ALDH1A1 838/4885
US-20190010126-A1 SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS TNNI3, TNKS1BP1, TNNT2 PDGFRB 3815/4885PDGFRA 2401/4885ALDH1A1 3674/4885
US-20020177606-A1 Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them QDPR, MRPL21, RPLP2 PDGFRB 4560/4885PDGFRA 4124/4885ALDH1A1 1808/4885
US-20070276168-A1 Method For Preparation Of A Fluoroaromatic Compound From An Aminoaromatic Compound DDC, NISCH, NAT1 PDGFRB 2229/4885PDGFRA 1943/4885ALDH1A1 1380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.